|1.||van Gilst, Wiek H: 6 articles (06/2015 - 09/2004)|
|2.||Egido, Jesús: 5 articles (11/2013 - 11/2003)|
|3.||Belenkov, Iu N: 4 articles (01/2006 - 01/2004)|
|4.||Watanabe, Kenichi: 4 articles (07/2004 - 02/2002)|
|5.||Rouleau, Jean L: 3 articles (06/2015 - 06/2002)|
|6.||Warnica, J Wayne: 3 articles (06/2015 - 11/2002)|
|7.||Khan, Bobby V: 3 articles (06/2012 - 05/2003)|
|8.||Johnstone, David: 3 articles (01/2008 - 11/2002)|
|9.||Baillot, Richard: 3 articles (01/2008 - 11/2002)|
|10.||Myers, Martin G: 3 articles (01/2008 - 11/2002)|
|1.||Hypertension (High Blood Pressure)
09/15/1990 - "Eleven patients with uncomplicated mild-to-moderate hypertension (diastolic pressure 95-115 mmHg) were treated for four weeks with daily single quinapril doses of 20-40 mg. Already during the second week a significant reduction in blood pressure was observed without increase of heart rate; 27.3% of patients responded to the lower dose (diastolic blood pressure [90 mmHg], and 54.6% responded to the higher dose. "
06/01/1990 - "Subsequent studies explored the safety and efficacy of quinapril in patients with mild to moderate hypertension and, later, in patients with more severe hypertension. "
09/01/1996 - "Quinapril, as used in current private clinical practice, is well tolerated and effective for the treatment of patients with stage 1 or 2 hypertension."
05/01/1992 - "We conclude that quinapril administered once daily is well tolerated and effective for the treatment of mild to moderate hypertension in elderly patients."
07/01/1992 - "Quinapril was shown to be a safe and effective treatment for patients with mild to moderate hypertension."
08/01/1994 - "Quinapril < or = 40 mg/day improved exercise tolerance, reduced the severity and frequency of symptoms, and improved functional (New York Heart Association) class in most clinical studies of patients with congestive heart failure. "
01/01/1986 - "The significant improvement in haemodynamic measurements acutely, following administration of Quinapril 5 mg orally, suggests that this drug is worthy of further study in the management of patients with refractory congestive cardiac failure, in particular its long term effects."
01/01/2002 - "In patients with congestive heart failure, quinapril <or=40 mg/day produced beneficial haemodynamic and echocardiographic changes and improved exercise tolerance, symptoms and functional class. "
11/15/1993 - "Quinapril is effective and safe for maintaining clinical stability in patients with moderate congestive heart failure. "
01/01/1998 - "Quinapril demonstrates improved endothelium-mediated vasodilation in patients with chronic heart failure."
|3.||Renal Insufficiency (Renal Failure)
01/01/2002 - "Quinapril overdose-induced renal failure."
01/01/1993 - "In conclusion, due to its long lasting effect on ACE activity and on blood pressure in terminal renal failure a starting dose of quinapril 2.5 mg o.d. "
04/01/1992 - "The renal clearance of quinapril and quinaprilat decreased with increasing renal insufficiency but did not result in significant changes in quinapril pharmacokinetics in patients with renal impairment. "
01/01/2005 - "Quinapril is more effective than amlodipine at reducing the incidence of dialysis in patients with progressive renal failure, but only if they can tolerate the drug. "
01/01/2005 - "A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure."
05/01/1997 - "Quinapril diminished ACE activity and ET-1 expression and synthesis coincidentally with an improvement in proteinuria and morphological lesions. "
12/01/2002 - "Quinapril, but not DZM, was able to diminish proteinuria in OZR. "
12/01/2002 - "Only quinapril was able to diminish proteinuria. "
07/01/1996 - "Quinapril prevented both proteinuria and morphological damage. "
12/01/1995 - "Administration of quinapril for three weeks to animals with glomerular lesions (proteinuria 20 to 50 mg/day) avoided the development of intense proteinuria (79 +/- 28 vs. 589 +/- 73 mg/day, P < 0.001) and decreased cell proliferation, glomerulosclerosis, tubulointerstitial lesions, and inflammatory infiltrates. "
09/01/2003 - "Furthermore, myocardial fibrosis was regressed and myocardial structure returned to nearly normal in animals treated with quinapril."
10/01/2001 - "The area of myocardial fibrosis was markedly reduced by quinapril (6+/-3%) as compared with controls (29+/-6%; p < 0.01). "
10/01/1991 - "Quinapril also limited vascular fibrosis development. "
08/01/2000 - "While the cause of the improved survival remains unknown, quinapril did apparently not interfere with the restitution of 'foetal' gene expression of pressure overloaded cardiomyocytes leading to depressed myocardial performance, ventricular dysfunction and the consecutive myocardial fibrosis."
04/01/2002 - "The effect of tranilast on cardiac fibrosis was comparable to the effects of a blood-pressure-decreasing dose of the ACE inhibitor, quinapril. "
|1.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|5.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|10.||Collagen Type I (Type I Collagen)
|1.||Sodium-Restricted Diet (Diet, Sodium Restricted)
|2.||Renal Dialysis (Hemodialysis)
|4.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|5.||Angioplasty (Angioplasty, Transluminal)